Price: quote on request. Your total cost is quoted in writing per case.
We reply within one business day
Get my quote

Myasthenia gravis (MG): US-approved treatments and how Gulf families can access them

A plain guide for families in the Gulf, checked against US FDA labels, Gulf drug registers and published medical research.

Reviewed by the Reserve Meds clinical operations team on 17 October 2026.

Myasthenia gravis: the short answer

The US FDA has approved six medicines on this page for myasthenia gravis, each for specific patients. Four of them are on at least one Gulf register we checked, so ask your hospital about local supply first. Otherwise the hospital can request a named-patient import. Reserve Meds is a digital health company. We do not diagnose or prescribe.

  • US FDA-approved medicines on this page: Vyvgart, Rystiggo, Imaavy, Zilbrysq, Soliris and Ultomiris.
  • Gulf registration (checked 17 October 2026): see each medicine below.
  • Legal route: Local supply where listed; otherwise a named-patient import request filed by the treating hospital.
  • Price: Quote on request.

What is myasthenia gravis?

Myasthenia gravis (MG) is a long-term autoimmune disease that causes weakness in the voluntary muscles, the ones used for eye and eyelid movement, facial expressions, chewing, talking, swallowing, breathing and moving the arms and legs. Weakness gets worse with activity and better with rest.[1]

In MG, the immune system makes antibodies that block signals at the junction where nerves meet muscles. Weakness often starts around the eyes, causing drooping eyelids and double vision. In generalized MG, the face, neck, arms, legs and breathing muscles can also be affected.[1, 2]

About 10 percent of people experience a myasthenic crisis, in which breathing muscles weaken so much that ventilation support is needed. Infections or reactions to medicines can trigger it. Newer US treatments for generalized MG work on antibodies or the complement system, and most require a positive antibody test.[2, 3, 4]

Myasthenia gravis in the Gulf

A Bahraini study of 98 MG patients at 3 hospitals found that 61.2% were female, pure eye-muscle disease at onset was most common (51%), and 57.1% had acetylcholine receptor antibodies.[5]

In 2025, neuromuscular experts from all six GCC countries published consensus recommendations for diagnosing and managing MG in the region.[6]

US FDA-approved medicines for myasthenia gravis

Each medicine below is approved in the US for a specific group of patients. The wording summarizes the current US label. Your specialist decides whether any of them is right for the patient.

  • Vyvgart (efgartigimod alfa)
    FDA-approved for adults with generalized myasthenia gravis. It is given by intravenous infusion. A separate product given under the skin is also available in the US.[3]
    Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.[7, 8]
    Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, Egypt, Turkey, India, Pakistan
  • Rystiggo (rozanolixizumab)
    FDA-approved for adults with generalized MG who are positive for acetylcholine receptor (AChR) or MuSK antibodies. It is an infusion under the skin.[9]
    Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.[7, 8]
    Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, Jordan, Lebanon
  • Imaavy (nipocalimab-aahu)
    FDA-approved for adults and children 12 years and older with generalized MG who are AChR or MuSK antibody positive. It is given by intravenous infusion.[10]
    Gulf registers: Saudi Arabia: not found by brand name in the SFDA drugs list. Abu Dhabi: not found by brand name in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.[7, 8]
  • Zilbrysq (zilucoplan)
    FDA-approved for adults with generalized MG who are AChR antibody positive. It is a daily injection under the skin.[4]
    Gulf registers: Saudi Arabia: not found by brand name in the SFDA drugs list. Abu Dhabi: not found by brand name in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.[7, 8]
    Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, Egypt, Jordan
  • Soliris (eculizumab)
    FDA-approved for adults and children 6 years and older with generalized MG who are AChR antibody positive. It is given by intravenous infusion.[11]
    Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.[7, 8]
    Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, Egypt, India, Pakistan
  • Ultomiris (ravulizumab)
    FDA-approved for adults with generalized MG who are AChR antibody positive. It is given by intravenous infusion.[12]
    Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.[7, 8]
    Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, India

How families in the Gulf can access these medicines

If the medicine is listed in your country. Ask your specialist and the hospital pharmacy about local supply first. A listing does not mean every hospital stocks the medicine, and another brand of the same medicine may also be registered, but local supply is usually the fastest route and you may not need us.

If it is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital pharmacy confirms.[13, 14] Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital pharmacy.

Who does what

  • Your treating specialist decides whether a medicine is right for the patient and writes the letter.
  • The hospital checks local supply, files any import request, and gives the treatment safely.
  • The national regulator decides whether to approve the import of a medicine that is not registered.
  • The manufacturer decides where its medicine can be supplied, especially for cell and gene therapies.
  • Reserve Meds helps organize records, coordinates US supply through our wholesale partner, shipping and updates to your family. We do not give medical advice.

Documents you will usually need

  • A letter from the treating specialist with the diagnosis, past treatments and why the medicine is being considered
  • Reports that confirm the diagnosis, such as laboratory, genetic, imaging or pathology results, translated into English where needed
  • Recent clinic notes and a list of current medicines
  • For a hospital import request: the prescription, the hospital's request form and the written consent of the patient or guardian
  • Proof of the US FDA approval and the US prescribing information (we can supply these)

We give you a written timeline estimate once we see the hospital file. The regulator, the treatment center and the manufacturer set their own timelines.

What treatment costs

Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

How Reserve Meds helps

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them.

Ask us about treatment for myasthenia gravis

Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.

Include the country code, for example +966 or +971.
Message us on WhatsApp

No account needed. We reply within one business day. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

Frequently asked questions

Is there an FDA-approved treatment for myasthenia gravis?

Yes. The medicines on this page have US FDA approval for specific groups of patients: Vyvgart, Rystiggo, Imaavy, Zilbrysq, Soliris and Ultomiris. The exact conditions are in each US label and are summarized above. Your specialist decides whether any of them fits.

Is Vyvgart available in Saudi Arabia or the UAE?

Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register. A listing in Abu Dhabi does not show federal UAE status.

How can a family in the Gulf get Vyvgart?

Ask the treating hospital about local supply first. If it is not available, the hospital can file a named-patient import request with the national regulator on your specialist's written request. Once approved, we arrange US supply to the hospital pharmacy.

How much does treatment cost?

Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.

Why does the antibody test matter?

Several US labels, for example Zilbrysq and Soliris, are limited to patients with acetylcholine receptor antibodies, and others include MuSK antibodies. Your neurologist confirms your antibody status before choosing a medicine.

What is a myasthenic crisis?

It is a dangerous weakening of the breathing muscles that may need ventilation support. MedlinePlus Genetics notes it can be triggered by infections or reactions to medicines. It needs emergency care.

Sources for the last two answers: [4, 9] [2]

Sources

Checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital pharmacy confirms the current position before filing.

  1. MedlinePlus (US National Library of Medicine): Myasthenia Gravis
  2. MedlinePlus Genetics (US National Library of Medicine): Myasthenia gravis
  3. DailyMed (US National Library of Medicine): Vyvgart (efgartigimod alfa) US prescribing information, version published 21 May 2026
  4. DailyMed (US National Library of Medicine): Zilbrysq (zilucoplan) US prescribing information, version published 5 February 2026
  5. Binfalah et al. Clinical delineation of myasthenia gravis in the Kingdom of Bahrain. Neurosciences (Riyadh) 2022 (PubMed 35017286)
  6. Alshehri et al. Consensus guidelines on the diagnosis and management of myasthenia gravis by the Saudi Arabia Neuromuscular and Electrodiagnostic Medicine and neuromuscular specialists from the Gulf Cooperation Council region. Ther Adv Neurol Disord 2025 (PubMed 40584517)
  7. SFDA: Drugs List, public register (all 9,173 entries checked by brand name on 17 October 2026)
  8. Department of Health Abu Dhabi: drug code list Drugs.xlsx (release 26 September 2026, effective 2 October 2026)
  9. DailyMed (US National Library of Medicine): Rystiggo (rozanolixizumab) US prescribing information, version published 21 January 2026
  10. DailyMed (US National Library of Medicine): Imaavy (nipocalimab-aahu) US prescribing information, version published 26 August 2026
  11. DailyMed (US National Library of Medicine): Soliris (eculizumab) US prescribing information, version published 13 July 2026
  12. DailyMed (US National Library of Medicine): Ultomiris (ravulizumab) US prescribing information, version published 17 November 2025
  13. SFDA: Special Access Program (SAP) guidance, version 1.0
  14. NHRA Bahrain: Circular No. (41) of 2020, procedures for importing non-registered medicines and pharmaceutical products

Related

This page is general health information, not medical advice. It does not replace a consultation with your doctor.

WhatsApp